Cost Effectiveness of Tofacitinib as Second Line Treatment Vs Using Biological Therapies In The Treatment of Moderate Rheumatoid Arthritis After Failure of Dmards In Guatemala In 2014
Abstract
Authors
M. Garita-Aguilar M. Peralta-Acon N. Chavez-Perez